A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors
Crossref DOI link: https://doi.org/10.1007/s00280-014-2567-9
Published Online: 2014-08-23
Published Print: 2014-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Becerra, Carlos R.
Conkling, Paul
Vogelzang, Nicholas
Wu, Hilary
Hong, Shengyan
Narwal, Rajesh
Liang, Meina
Tavakkoli, Fatemeh
Pandya, Naimish
License valid from 2014-08-23